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Summary DT-diaphorase (DTD) is an important enzyme for the bioreductive activation of the new
alkylating indoloquinone E09. In preclinical studies, E09 has shown selective anti-tumour activity against
solid tumours and under hypoxic conditions. The levels of three reductive enzymes have been determined in
three types of human solid tumours, together with corresponding normal tissues and normal liver. DTD
enzyme activities were measured in tumour extracts using 2,6-dichlorophenolindophenol (DCPIP) and NADH
as substrates; cytochrome P450 reductase or cytochrome b5 reductase activities were assessed with cytochrome
c and NADPH or NADH respectively. DTD activity was highest in non-small-cell lung (NSCLC) tumours
(mean 123 nmol DCPIP min' mg-'), followed by colon carcinoma (mean 75 nmol minm mg-') and
squamous cell carcinoma of the head and neck (6-fold lower than NSCLC). DTD activity was very low in
normal liver and normal lung (4-6 nmolmin-'mg-'), while the levels in normal colon mucosa or normal
mucosa of the head and neck region were in the same range as the corresponding tumours. The levels of the
two other reductive enzymes, cytochrome P450 reductase (CP450R) and cytochrome b5 reductase (Cb5R),
were 5 to 25-fold lower than those of DTD in all the tissues, except for normal liver, in which DTD was 2 to
4-fold lower. The degree of variation found for DTD (range 4-250 nmol min-' mg-'), was not observed for
these enzymes (CP450R, 0.8-7.8nmol cytochrome cmin1'mg-1; Cb5R, 3.5-27.6nmolmin-'mg-'). It is
anticipated that NSCLC patients are more likely to respond to E09 and other bioreductive agents, owing to
the high levels of the activating enzyme in this tumour type. To prove that this assay has predictive value we
need to study these enzyme levels in tumour samples obtained from patients on clinical studies with
bioreductive agents.
Keywords: DT-diaphorase; head and neck squamous cell carcinoma; cytochrome b5 reductase; cytochrome
P450 reductase; bioreductive agents; E09.
DT-diaphorase (DTD, ECI.6.99.2) is considered to be the
most important enzyme for the activation of bioreductive
drugs such as E09 and diaziquone (AZQ); at low pH it can
also reduce mitomycin C (MMC) [Siegel et al., 1990; Work-
man et al., 1990; Walton et al., 1991; Riley and Workman,
1992; Siegel et al., 1992; Workman, 1992]. DTD is present in
many mammalian tissues, where it can play a role in the
biosynthesis ofvitamin K (Wallin et al., 1978; Ernster, 1987),
or may act as a detoxifying enzyme, by catalysing a strict
two-electron reduction (Benson et al., 1980; Ernster, 1987).
For AZQ and E09 this reduction however leads to bioactiva-
tion of reactive groups, inducing their toxic properties such
as DNA damage (Siegel et al., 1990; Workman et al., 1990;
Walton et al., 1991; 1992a). E09, a bioreductive alkylating
indoloquinone, is a structural analogue of MMC and has
shown selective activity against solid tumour types, in vitro
and in animal models (Oostveen and Speckamp, 1987; Hend-
riks et al., 1993). Clinical phase I trials with E09 have just
been finished (Schellens et al., 1994).
Several studies have been published recently, in which a
correlation was postulated between the DTD levels (both
expression and activity) and the chemosensitivity to E09
under normoxic conditions (Robertson et al., 1992; Walton
et al., 1992b; Plumb et al., 1994a; Smitskamp-Wilms et al.,
1994). For other reductive enzymes such as the one-electron-
donating NADH cytochrome b5 reductase (Cb5R) and
NADPH cytochrome P450 reductase (CP450R) no such rela-
tion with E09 sensitivity was found in more than 20 human
tumour cell lines (Ross et al., 1993; Plumb et al., 1994a,c). It
has however been reported that CP45OR can reduce E09
(Bailey et al., 1994). Under hypoxic conditions the role of
DTD is less clear; it seems that in cells with low DTD other
reductases play a more prominent role under low-oxygen
conditions, while metabolism of E09 by DTD dominates in
DTD-rich cells, in both air and hypoxia (Plumb et al.,
1994a,b,c; Robertson et al., 1994). On the other hand, Yao et
al. (1994) observed a 3- to 5-fold increase in DTD and
CP45OR mRNA by exposing a colon cell line to hypoxia.
Apart from hypoxia, expression of DTD can also be induced
by chemical inducers (Benson et al., 1980; Prochaska and
Talalay, 1988), including cytotoxic drugs or carcinogens.
Several reports have mentioned higher DTD levels (both
activity or mRNA) in tumour cells compared with normal
tissues (Schor and Cornelisse, 1983; Schlager and Powis,
1990; Cresteil and Jaiswal, 1991), although not for all tumour
types (Schlager and Powis, 1990).
The logical sequel to these studies would be to investigate
the relation between DTD and sensitivity to bioreductive
drugs in human tumour tissues. In this way it will be possible
to select suitable tumours for treatment with, for example,
E09, following the 'enzyme directed approach' as put for-
ward by Workman and Walton (1990). Therefore, we
measured DTD levels in a number of human normal (from
colon, lung, liver, blood and head and neck) and neoplastic
tissues (from colon, lung and head and neck) to determine
whether, and if so in which tumour types, E09 would exert
selectivity. The activity of two one-electron reductases, Cb5R
and CP450R, was measured for comparison and because of
their possible role in the activation of E09 under hypoxia
(Plumb et al., 1994b,c; Robertson et al., 1994).
Materials and methods
Patient characteristics
Biopsy specimens of primary colon tumours (CT, n = 8),
metastases [Met, n = 4: three in liver (patients 10, 21 and 31)
and one lymph node metastasis (patient 25)], normal mucosa
(Muc, n=4) or liver (Liv, n = 6) were obtained from 18
patients with colorectal cancer. Thirteen ofthem had received
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one i.v. bolus injection of 5-fluorouracil (SFU; 500 mg m-2)
before surgery and have been described previously (Peters et
al., 1993, 1994). The other five samples (CT 0'; Muc 3'; Liv
1', Liv 2' and Liv 3') were obtained from untreated patients
(no chemotherapy at the time of surgery). From several
patients both tumour and normal tissues were acquired (sam-
ples with the same number).
The second group consisted ofeight patients suffering from
squamous cell carcinoma (SCC) of the head and neck region;
three oropharynx, two hypopharynx, one supraglottic, two
floor of the mouth. Five of them had received radiotherapy
before surgery. From all of these patients, tumour tissue was
removed together with adjacent intermediate tissue and nor-
mal appearing tissue, which were stored separately. Strict
non-neoplastic tissues from the head and neck region
(uvulae) were obtained from non-cancer patients undergoing
reconstructive palato-pharyngeal surgery. These samples were
treated in the same way as the tumours.
All the lung specimens were obtained from patients with
non-small-cell lung cancer (NSCLC) undergoing radical
resection. Four tumours were classified as squamous cell
carcinoma (SCC), one as an adenocarcinoma (AD), one as
combined adenosquamous (AS) and one as large cell (LC).
All patients had a smoking history.
Blood was taken from a healthy volunteer. After cent-
rifugation, the fraction with the red cells was sonicated on
ice.
Sample preparation
Biopsy specimens were obtained from several tumours and
histologically confirmed. Adjacent normal appearing tissue
was frozen separately. Normal and tumour tissues had been
frozen immediately after surgery in liquid nitrogen and kept
at -80°C. At the day of the enzyme assays, the still frozen
tumour was cut into small pieces (with a total weight of
maximum ± 100 mg) and was pulverised in a liquid nitrogen-
cooled vessel using a microdismembrator (B Braun, Mel-
sungen, Germany, Peters et al., 1986). Thus during the whole
procedure the tumour was kept frozen. The powder was
homogenised by vortexing in ice-cold Tris-HCI buffer
(25 mM, pH 7.4) at 1 g of tissue per 6 ml of buffer and
centrifuged for 5 min at 4000 r.p.m. at 4°C. After removal of
the fatty layer, the supernatant was subsequently centrifuged
for 15 min at 14000 r.p.m. at 4°C. The second supernatant
was used for enzyme measurements. If necessary, it was
diluted 5-10 times in 25 mM Tris buffer. A small sample of
the enzyme extract was frozen again in liquid nitrogen and
kept for several months at - 80°C to test stability. DTD
activity was stable for at least 6 months (results not shown).
Reproducibility was tested by extracting samples of one
biopsy specimen at different time points. Inter- and intra-
assay variation was less than 10%. Protein concentrations
were determined according to Bradford (1976).
Bioreductive enzyme assays
DTD was measured spectrophotometrically as described ear-
lier for cell lines, except that addition of bovine serum
albumin (BSA) as activator or stabiliser was not necessary
(Smitskamp-Wilms et al., 1994). Briefly, the reaction was
performed in a total volume of 3 ml, containing 25 mM Tris
pH 7.4; 40AM dichlorophenolindophenol (DCPIP) as subs-
trate and 0.2 mM NADH as co-factor (final concentrations).
The reduction was measured at room temperature for
1-3 min at 600 nm with or without the inhibitor dicoumarol
(100IM). DTD activity is considered to be the dicoumarol-
inhibitable part of the DCPIP reduction. The reaction was
started by addition of at least three different volumes of the
supernatant (0.2-50fd 3 ml-'), which enabled us to study
linearity. When measuring DTD activity in the blood sam-
ples, the same volume of sonicated red blood cells was added
to both cuvettes, to compensate for the high absorbance
caused by the haemoglobin.
NADH cytochrome bS reductase and NADPH cytochrome
P450 reductase activity were measured at 550 nm under
similar conditions, using as a substrate 77 JLM cytochrome c
and as co-factors 0.2 mM NADH or 0.2 mM NADPH re-
spectively. Cytochrome c is not a substrate for DTD, while
DTD has no preference for either of the co-factors (Ernster
et al., 1962). Units of activity were expressed as nmol DCPIP
reduced min- mg-' protein for DTD and as nmol cytochro-
me c reduced min- mg-' protein for NADH cytochrome b5
reductase and NADPH cytochrome P450 reductase.
Control experiments concerning induction of DTD by 5FU
or E09 were performed on the colon carcinoma cells lines
SW620 and WiDr. DTD activity was determined as described
previously (Smitskamp-Wilms et al., 1994) 24 h after
exposure to 25l4M 5FU or 30 nM E09 (IC50 values). 5FU
concentrations in the colon tumours varied from
0.17-21.61.M (Peters et al., 1993).
Statistical evaluation
Statistical evaluation of the differences between the samples
was tested using the Mann-Whitney U-rank-sum test.
Results
Measurement of DTD activity in tumour tissues that has
been stored frozen, is feasible. To assay DTD no more than
60 mg of frozen tissue is required compared with 105 cells,
when cell lines were used (Smitskamp-Wilms et al., 1994).
The DTD activity in the different tissue types are depicted in
Figure la, b and c. As a group DTD activity was highest in
NSCLC tumours, followed by colon tumours and metastases
(three liver and one lymph node) of colon tumours. Normal
lung and liver tissue and squamous cell carcinoma of the
head and neck contained low DTD activity (Table I). In the
sets of paired tissues obtained from three NSCLC patients,
all tumours clearly had significantly elevated DTD levels
(P = 0.008) compared with normal lung tissues (7-, 12- and
66-fold higher; Figure ic). In colon mucosa, this difference
was less clear. From the three paired samples, the DTD
activity was three times lower in one mucosa than in the
corresponding tumour (patient 7), while in the other two
patients (patients 19 and 55), there was no difference in DTD
activity (Figure la). The colon tumours showed a varying
range of DTD activities. In four of the primary colon
tumours, DTD activity was higher than 46 nmol min-' mg-'.
In the other four, in the colon cancer metastases (three liver
and one lymph node) and in normal colon mucosa,
intermediate levels were found (2-31 nmolmin-' mg- 1),
while in normal liver it was very low (4 nmolmin' mg-').
This means that the metastatic tissue is more similar to the
primary tumour than to the local liver tissue (Figure la).
Thirteen of the patients in the colon cancer group had
received a single injection of 5FU just before the surgery.
However, DTD activities in the three livers from treated
patients (1', 2', 3') were not different from the three control
(no 5FU) livers (patients 17, 57, 58). Similarly, other samples
from untreated patients (primary tumour and mucosa) had
DTD levels in the same range as that of treated patients. As
a control, possible induction by 5FU or E09 was measured
in two colon carcinoma cell lines. Both in SW620 and WiDr
cells, no induction by these compounds was observed after
24 h exposure to IC50 concentrations (results not shown).
In the head and neck tumours we observed low to
intermediate DTD levels. In these tumours the activity was
much lower than in the lung and colon tumours; in addition
the activity was not significantly different from normal
(Mann-Whitney U-test: P = 0.4) or intermediate (P = 0.14)
tissues, including normal tissue from non-cancer patients
(Table 1, Figure lb).
In normal liver, DTD activity measured as DCPIP reduc-
tion was very low (4 nmol min lmg-'). Whereas in the
tumour extracts low concentrations of dicoumarol almost
completely inhibited the enzyme activities (>90%) similar to






























Figure 1 DTD levels in human tissues. Indicated is the site of the sample and the type of tissue ( = tumour; , normal
tissue), followed by a patient's number (abbreviations used as described in Materials and methods). (a) CT, colon tumour; Muc,
normal colon mucosa; Liv, normal liver; Met, metastasis, from primary colon cancer; Patients' numbers followed by ' did not
receive a 5FU injection; (b) HN, head and neck; (c) L, NSCLC patients.
Table I DTD activities in human tumour and normal tissues
DTDa
Origin Tissue type mean ± s.d. Median Range nb
Colon Primary tumour 75* + 87 48 10-290 8
Normal mucosa 30 20 25 13-55 4
Lymph node 18 1
Metastasis
Liver metastasis 17.4* ± 12.1 20 1-31 3
Liver Normal 3.7 ± 0.7 3.9 3-5 6
Lung NSCLC 123**+ 74 138 16-250 7
Normal 6.4±4 6.9 2-10 3
Head and neck SSC tumour 21* 12.6 21 4-34 8
Intermediate 30.7* ± 14.9 27.4 10-50 8
Normal 19.5 7.2 19.4 7-29 8
Uvulaec 57* 34 54 14-100 3
IDTD activity: mean ± standard deviation (s.d.), unit: nmol min' mg-'.
bn = number of individual samples (biopsy specimen). cNormal tissue from non-cancer
patients. *Not significantly different from corresponding normal tissue (P>0.05).
**Significantly different from normal tissue (P= 0.008). The Mann-Whitney U-test
was employed for statistical analysis. Level of significance is set at P<0.05.
of the reduction of DCPIP. This indicates the presence of
other enzymes that are able to reduce DCPIP. This was
confirmed by measuring the activity of Cb5R and CP45OR
(Figure 2). In all tested tumours and colon mucosa these
one-electron-donating enzymes were less abundant than
DTD (Table II), although it is difficult-to draw an exact
parallel since substrates differ. Levels varied between 5% and
60% of that of DTD (range 3.5-27.6 nmol min' mg',
median 13 nmol min' mg-'). In contrast, the liver extracts
contained much higher Cb5R activity compared with that of
DTD (230-470%), although the absolute activities were in
the same range (7.6-23nmol min' mg-1) as in the colon
tissues. Also, absolute CP45OR activities were similar among
liver and other tissues (range 0.8-7.8 nmol min
-' mg -). But,
relative to DTD, in normal liver CP45OR activities were
higher than in other tissues.
DTD could not be detected in red blood cells. Although
DCPIP was being reduced at a relatively low level
(5 nmol min' mg-' protein or 300 nmol min lml-' red
blood cells), this reduction could not be inhibited by
dicoumarol.
Similar to the DTD activity in cell lines (Smitskamp-Wilms
et al., 1994), we noticed variations in the linearity of the
assay depending on the source of tissue. For some of the
samples with high DTD activity (>50 nmol min' mg' or
>250 nmol min- ml-'), it was necessary to use higher dilu-
tions in order to perform measurements in the linear range.
This range varied per sample but in general was in the low
protein range (<60 gLg per assay) for samples with high
activity (> 50 nmol min' mg-'). For tissues with an activity
lower than 25 nmol min- mg-' (or <100 nmol min'I ml-'),
this range was less narrow and went up to 300 tg per
assay.
Discussion
In this study we demonstrate that only in human lung
tumours (NSCLC) DTD activity was significantly higher
than in normal tissues. In the other tumour types inves-
tigated (colon, including some metastases, and SSC of the
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Figure 2 One-electron reductase (i, NADH cytochrome b5
reductase; _, NADPH cytochrome P450 reductase) activity in
human tissues. The sample codes are the same as used in Figure
1. SQ, squamous cell carcinoma; AS, combined adenosquamous;
AD, adenocarcinoma; LC, large cell.
DTD activity in these tumours was also lower than in lung
tumours.
These high levels in NSCLC samples are in agreement with
the data reported by Malkinson et al. (1992); Ross et al.
(1993). Much higher DTD levels were found in NSCLC
compared with small-cell lung cancer and normal lung.
Generally, DTD levels in cell lines derived from NSCLC
were higher than in small-cell lung cancer (SCLC) cell lines
or other cell lines (Malkinson et al., 1992; Robertson et al.,
1992, 1994). These results indicate that NSCLC is more likely
to be sensitive to E09 than other tumour types (Ross et al.,
1993; Stratford et al., 1994). Consequently, NSCLC is one of
the diseases selected for phase II clinical trials.
Several reports mentioned that the activity of DTD is
higher in tumour cells than in normal cells of the same origin
(Schor and Cornelisse 1983; Schlager and Powis 1990;
Cresteil and Jaiswal 1991; Malkinson et al., 1992). This has
been found in primary tumours of lung, liver, colon, breast
and testis (Schlager and Powis, 1990). However, in tumours
from kidney and stomach, lower enzyme activities were
found when compared with normal tissue (Schlager and
Powis 1990; Eickelmann et al., 1994). In this study, in addi-
tion to small differences between normal colon mucosa and
primary colon tumours, we found that head and neck
tumours showed the same activity pattern as the surrounding
normal tissues. Normal tissue from the head and neck region
from non-cancer patients showed the same DTD levels,
indicating that the results were not influenced by their loca-
tion with respect to the tumour.
Studies on regulation of expression of DTD (Prochaska
and Talalay 1988; Cresteil and Jaswail 1991: Belinsky and
Jaiswal 1993) indicated that DTD can be induced by
cytotoxic drugs. However, our results show no difference in
DTD activities between three livers from patients who had
Table II Reductive enzymes in a set of human tissues (subset ofthe
samples mentioned in Table 1)
Reductive enzymes
DTDa CbSR CP45ORb n
nmol DCPIP nmol Cyt c nmol Cyt c
Tumour type min,' mg' min- ' mg ' mini' mg'
Normal liver 3.9 15.5 6.7 (5)
NSCLC 138 13.3 5.lb (4)
Colon tumour 119 17.8 3.6b (4)
Colon mucosa 35.6 6.9 5.7 (3)
aValues are means of n samples (as indicated within parentheses),
bexcept for CP45OR in NSCLC and colon tumours where n = 1.
Intra-assay variation among duplicates was < 10%.
been treated with 5FU and three liver samples from un-
treated patients (LIV 1', 2' and 3'). Also in vitro no induction
by physiologically relevant concentrations of 5FU or E09
was observed.
The very low DTD activities in human normal liver are in
sharp contrast to DTD in rodent normal livers (Schlager and
Powis 1990). Differences in kinetic behaviour of isolated rat
and human DTD as described by Boland et al. (1991)
emphasise again that rodent models are not always appropri-
ate models for human drug therapy.
One-electron reductase activities in tumour tissues were
2-60% compared with that of DTD, while cytochrome b5
reductase levels were always higher than those ofcytochrome
P450 reductase. This was in line with other studies, reporting
levels varying around 20% of that of DTD (Schlager and
Powis 1990; Walton et al., 1992; Hendriks et al., 1993; Ross
et al., 1993). Relatively high levels of these enzymes con-
tribute to the reduction of DCPIP in the DTD assay, as was
noticed in normal liver. In these samples, total reductase
activity on DCPIP could be inhibited only by 50% by
dicoumarol. Although no correlation between the levels of
these enzymes (measured under aerobic conditions) and E09
cytotoxicity in cell lines was found, it is conceivable that
these enzymes play a role in the hypoxic part of the tumour
(Plumb et al., 1994a,c). However, the small differences among
the several tissue types rule out a possible role as predictive
marker for these enzymes.
The potency of E09 under hypoxic conditions (Adams et
al., 1992) makes it an interesting compound to combine with
radiation. Since encouraging results have been found in pre-
clinical studies using cell lines and rats, clinical trials with
this combination should be considered (Adams and Stratford
1994; Kal et al., 1994; Stratford et al., 1994).
Correlations between E09 sensitivity and DTD activity in
vivo are limited to only a few murine models (Workman et
al., 1990; Walton et al., 1992) and rat (Kal et al., 1994).
Although the relation was positively similar to that found in
in vitro studies, DTD levels in patients entering clinical trials
should be measured since these levels are expected to have
predictive value. High DTD levels would be associated with a
response to E09. This is in line with the theory of enzyme
profiling before determining therapy, as suggested by Work-
man and Walton (1990; Riley and Workman 1992; Walton et
al., 1992b).
In conclusion, based on these observations in human
tumours (absolute activity and relative to normal tissue),
patients with NSCLC and those with colon tumours are
more likely to be sensitive to E09 than those with squamous
cell carcinoma of head and neck. This should be validated by
measuring DTD levels in patients undergoing E09 treatment,
such as those participating in the clinical trials.
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